GR 131663
Alternative Names: AH 017Latest Information Update: 10 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Sleep disorder therapies; Small molecules
- Mechanism of Action Melatonin MT1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 12 Mar 1997 No-Development-Reported for Sleep disorders in United Kingdom (Unknown route)